发明名称 |
Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion |
摘要 |
This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4<SUP>+</SUP> cell, but not a T cell-tropic isolate of HIV-1 to a CD4<SUP>+</SUP> cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4<SUP>+</SUP> cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD 4 <SUP>+</SUP> cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4<SUP>+</SUP> cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4<SUP>+</SUP> cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4<SUP>+</SUP> cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.
|
申请公布号 |
US2006140977(A1) |
申请公布日期 |
2006.06.29 |
申请号 |
US20050259540 |
申请日期 |
2005.10.25 |
申请人 |
PROGENICS PHARMACEUTICALS, INC. |
发明人 |
ALLAWAY GRAHAM P.;LITWIN VIRGINIA M.;MADDON PAUL J. |
分类号 |
C12Q1/68;A61K38/00;A61K39/12;C07K16/28;G01N33/569 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|